FAP-Targeted LTBR Antibody Combination for Cancer Treatment
Summary
Hoffmann-La Roche Inc. filed US Patent Application US20260109767A1 on December 17, 2025, covering combination therapies using FAP-targeted lymphotoxin beta receptor (LTBR) antibodies and tumor-targeted anti-CD3 bispecific antibodies as T cell engagers for cancer treatment. The application names Roberta Bianchi, Ralf Joerg Hosse, Leo Frederik Kunz, and Pablo Umaña Fernández as inventors. Patent claims are directed to the antibody combinations and methods of treating cancer using these therapies.
“The present invention relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies (T cell engager) and FAP-targeted LTBR antibodies, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
US Patent Application US20260109767A1 was published on April 23, 2026, disclosing combination therapies employing FAP-targeted LTBR (lymphotoxin beta receptor) agonist antibodies and tumor-targeted anti-CD3 bispecific antibodies as T cell engagers for the treatment of cancer. The application covers the antibody compositions, methods of manufacturing, and methods of treating cancer using the combination.
Affected parties include pharmaceutical and biotechnology companies developing cancer immunotherapies, particularly those working in the FAP (fibroblast activation protein) or LTBR pathway space. The publication of this patent application may have freedom-to-operate implications for competitors developing similar bispecific antibody or FAP-targeted oncology therapies.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMBINATION THERAPY WITH FAP-TARGETED LYMPHOTOXIN BETA RECEPTOR AGONISTS
Application US20260109767A1 Kind: A1 Apr 23, 2026
Assignee
Hoffmann-La Roche Inc.
Inventors
Roberta BIANCHI, Ralf Joerg HOSSE, Leo Frederik KUNZ, Pablo UMAÑA FERNÁNDEZ
Abstract
The present invention relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies (T cell engager) and FAP-targeted LTBR antibodies, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
CPC Classifications
C07K 16/2809 A61P 35/00 C07K 16/2878 C07K 16/3007 A61K 2039/507 C07K 2317/31 C07K 2317/52 C07K 2317/55 C07K 2317/565 C07K 2317/75
Filing Date
2025-12-17
Application No.
19424027
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.